Business Context and Reporting Period
Company: Oruka Therapeutics, Inc. (formerly ARCA biopharma, Inc.)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024 (Inception: February 6, 2024)
Business Overview: Oruka is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. The company operates as a single reportable segment.
Key Event: On August 29, 2024, the company completed a reverse recapitalization merger with Pre-Merger Oruka, changing its name and ticker symbol to "ORKA".
Key Financial Metrics
| Metric | Value (In Thousands) |
|---|---|
| Revenue | $0 (No product sales to date) |
| Net Loss | $(83,724) |
| Operating Expenses | $88,123 |
| - Research & Development | $75,060 |
| - General & Administrative | $13,063 |
| Cash, Cash Equivalents, and Marketable Securities | $393,700 (as of Dec 31, 2024) |
| Net Cash Used in Operating Activities | $(57,837) |
| Net Cash Provided by Financing Activities | $449,539 |
| Debt | $0 (Convertible note converted to equity prior to year-end) |
Material Changes and Operational Highlights
- Merger and Rebranding: The company completed a reverse recapitalization with Pre-Merger Oruka in August 2024, adopting the name Oruka Therapeutics, Inc. and ticker ORKA. A 1-for-12 reverse stock split was effected in September 2024.
- Capital Raising: The company raised significant capital through a Pre-Closing Financing (approx. $275 million gross) and a PIPE Financing (approx. $200.5 million gross) in 2024.
- Pipeline Progress:
- ORKA-001 (IL-23p19): Phase 1 trial in healthy volunteers initiated in Q4 2024. Interim data expected in H2 2025.
- ORKA-002 (IL-17A/F): Phase 1 trial in healthy volunteers planned for Q3 2025.
- Related Party Transactions: Significant R&D expenses ($42.0 million) were incurred related to Option and License Agreements with Paragon Therapeutics, Inc. and Paruka Holding LLC.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management expects existing cash, cash equivalents, and marketable securities ($393.7 million) to fund operations for at least twelve months from the filing date.
- Profitability: The company has incurred significant losses since inception and anticipates continuing to incur losses for the foreseeable future as it advances clinical trials. No revenue is expected from product sales in the near term.
- Key Risks:
- Development Risk: Dependence on the success of ORKA-001 and ORKA-002; clinical trials may fail or be delayed.
- Capital Requirements: Need to raise additional capital to fund future operations; failure to do so could require curtailing development.
- Third-Party Reliance: Reliance on Paragon for discovery and development, and third-party CMOs for manufacturing.
- Regulatory: Lengthy and uncertain FDA approval process.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $393.7 million cash balance against projected burn rates for clinical trials.
- Paragon Agreements: Review the terms of the Option and License Agreements with Paragon, specifically milestone payment obligations (up to $22 million total per program) and royalty rates.
- Clinical Timelines: Monitor the initiation of Phase 1 trials for ORKA-001 and ORKA-002 and the release of interim pharmacokinetic data in 2025.
- Dilution: Assess the impact of outstanding pre-funded warrants, employee warrants, and potential future equity financings on shareholder ownership.
- Manufacturing: Confirm the status of third-party manufacturing agreements and any potential supply chain risks associated with foreign CMOs.